Fibrocell Science, a cell and gene therapy developer, has agreed to be acquired by Castle Creek Pharmaceuticals for $63.3 million. As part of the deal, Castle Creek will pay Fibrocell an upfront payment of $7.5 million plus milestone payments of up to $135 million related to its new drug candidates.
Castle Creek to acquire Fibrocell in $63.3M deal
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.